Entremed (ENMD)

[Rocky I]

EntreMed Stockholders Approve Name Change To CASI Pharmaceuticals




Common stock to begin trading under "CASI" on June 16, 2014

ROCKVILLE, Md., June 13, 2014 /PRNewswire/ --- EntreMed, Inc. ENMD
-1.35% , a clinical-stage biopharmaceutical company developing
therapeutics for the treatment of cancer and other diseases, announced
today that at its annual meeting of stockholders held on June 12,
2014, stockholders voted in favor of changing the company's corporate
name to CASI Pharmaceuticals, Inc. The name change will occur on June
16, 2014 with the Company's common stock trading on NASDAQ under the
new symbol "CASI" and the rollout of a new website
www.casipharmaceuticals.com .

"Changing our name is an important milestone as it represents another
step toward completing our company's transformation," said Ken K. Ren,
Ph.D., EntreMed's chief executive officer. "Our operations and
strategic focus have evolved and today have little resemblance to our
legacy years. Our name change is another step towards our mission to
build a new and leading biopharmaceutical company targeting global
markets with a focus on China."